TD Cowen lowered the firm’s price target on Cue Health to $1.50 from $5.00 and keeps an Outperform rating on the shares. The firm said the company expects approvals for its new respiratory tests may come as early as upcoming respiratory season. Cowen sees test approvals as next major catalyst for company.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HLTH: